Safety and Efficacy of Toripalimab in HER2- Metastatic Breast Cancer Patients Treated With Metronomic Vinorelbine
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: Vinorelbine 40mg|BIOLOGICAL: Toripalimab 240mg|BIOLOGICAL: Bevacizumab 5 mg/kg|DRUG: Cyclophosphamide 50 mg|DRUG: Capecitabine 500Mg Oral Tablet|DRUG: Cisplatin
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Collaborators: Beijing Huanxing Cancer Hospital